Biotech · Private company
Oscotec Inc.
Track this companyFree. Adds Oscotec Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- SKI-O-703Phase 2 · Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
- SKI-O-703Phase 2 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- .[14C]-SKI-O-703Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- SKI-G-801Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01PHASE1 · TERMINATED · started Feb 6, 2024ClinicalTrials.gov NCT06247345 · fetched Nov 12, 2026
- A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male SubjectsEARLY_PHASE1 · COMPLETED · started Aug 10, 2021ClinicalTrials.gov NCT05042986 · fetched Nov 12, 2026
- Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)PHASE2 · COMPLETED · started Oct 11, 2019ClinicalTrials.gov NCT04056195 · fetched Nov 12, 2026
- A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.PHASE2 · COMPLETED · started Mar 20, 2019ClinicalTrials.gov NCT04057118 · fetched Nov 12, 2026
- Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)PHASE1 · COMPLETED · started Feb 23, 2018ClinicalTrials.gov NCT03564288 · fetched Nov 12, 2026